US Stock MarketDetailed Quotes
BIIB Biogen
- 181.690
- -2.170-1.18%
Close Oct 25 16:00 ET
- 182.590
- +0.900+0.50%
Pre 06:26 ET
26.47BMarket Cap22.91P/E (TTM)
187.580High181.245Low1.72MVolume185.700Open183.860Pre Close315.90MTurnover1.19%Turnover Ratio22.80P/E (Static)145.66MShares268.29552wk High1.67P/B26.37BFloat Cap181.24552wk Low--Dividend TTM145.12MShs Float480.180Historical High--Div YieldTTM3.45%Amplitude2.625Historical Low183.640Avg Price1Lot Size
Biogen Stock Forum
Sign in to post a comment
Morning Movers
Gapping up
$Meta Platforms (META.US)$ stock rose 8.9% following stronger-than-expected second-quarter earnings and a positive future outlook.
$ConocoPhillips (COP.US)$ stock increased by 0.8% after reporting a second-quarter profit that surpassed estimates, aided by higher output and oil prices.
$Ferrari (RACE.US)$ stock climbed 3.3% as the company raised its full-year revenue and core earnings forecasts, having ex...
Gapping up
$Meta Platforms (META.US)$ stock rose 8.9% following stronger-than-expected second-quarter earnings and a positive future outlook.
$ConocoPhillips (COP.US)$ stock increased by 0.8% after reporting a second-quarter profit that surpassed estimates, aided by higher output and oil prices.
$Ferrari (RACE.US)$ stock climbed 3.3% as the company raised its full-year revenue and core earnings forecasts, having ex...
31
3
by Luzi Ann Santos | moomoo News
U.S. stocks advanced as $NVIDIA (NVDA.US)$, $Microsoft (MSFT.US)$, $Amazon (AMZN.US)$ and $Meta Platforms (META.US)$ rebounded after the latest U.S. economic data bolstered the case for the Federal Reserve to start cutting interest rates in the next few months.
The $S&P 500 Index (.SPX.US)$ rose 1.1% to close at 5459.10, while the tech-heavy $Nasdaq Composite Index (.IXIC.US)$ gained 1.03% to 17,...
U.S. stocks advanced as $NVIDIA (NVDA.US)$, $Microsoft (MSFT.US)$, $Amazon (AMZN.US)$ and $Meta Platforms (META.US)$ rebounded after the latest U.S. economic data bolstered the case for the Federal Reserve to start cutting interest rates in the next few months.
The $S&P 500 Index (.SPX.US)$ rose 1.1% to close at 5459.10, while the tech-heavy $Nasdaq Composite Index (.IXIC.US)$ gained 1.03% to 17,...
+1
98
14
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Keep an eye on these recently announced M&As: 👀
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
6
$Biogen (BIIB.US)$ perhaps some puts on this 0.0
Keep an eye on these M&As: 👀
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Harmony Biosciences (HRMY.US)$ acquired Epygenix Tx
What companies will be next? 🤔
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Harmony Biosciences (HRMY.US)$ acquired Epygenix Tx
What companies will be next? 🤔
7
$Biogen (BIIB.US)$ 📣 Acquires Human Immunology Biosciences (HI-Bio)
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
4
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
7
Tesla, Visa and Boeing are popping in pre market after reporting their earnings.
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR S&P 500 ETF (SPY.US)$ $S&P 500 Index (.SPX.US)$ $Visa (V.US)$ $Boeing (BA.US)$ $Texas Instruments (TXN.US)$ $Biogen (BIIB.US)$ $Airbnb (ABNB.US)$ $Bank of America (BAC.US)$ $Disney (DIS.US)$ $Apple (AAPL.US)$ $Meta Platforms (META.US)$ $Microsoft (MSFT.US)$ $NVIDIA (NVDA.US)$ $Taiwan Semiconductor (TSM.US)$ $Super Micro Computer (SMCI.US)$ $Coinbase (COIN.US)$ $Alphabet-A (GOOGL.US)$
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR S&P 500 ETF (SPY.US)$ $S&P 500 Index (.SPX.US)$ $Visa (V.US)$ $Boeing (BA.US)$ $Texas Instruments (TXN.US)$ $Biogen (BIIB.US)$ $Airbnb (ABNB.US)$ $Bank of America (BAC.US)$ $Disney (DIS.US)$ $Apple (AAPL.US)$ $Meta Platforms (META.US)$ $Microsoft (MSFT.US)$ $NVIDIA (NVDA.US)$ $Taiwan Semiconductor (TSM.US)$ $Super Micro Computer (SMCI.US)$ $Coinbase (COIN.US)$ $Alphabet-A (GOOGL.US)$
From YouTube
5
5
Morning Movers
Gapping up
$Tesla (TSLA.US)$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T (T.US)$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa (V.US)$ stock grew 2.4% as the credit card company's second...
Gapping up
$Tesla (TSLA.US)$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T (T.US)$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa (V.US)$ stock grew 2.4% as the credit card company's second...
24
1
... 
The pharma giant $Eli Lilly and Co (LLY.US)$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
70
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
webguybob : The Etsy downgrade surprised me!
105535782 : ok
102242135 Lim : K